SUDEEP PHARMA LIMITED

21 Nov 2025 - 25 Nov 2025 Individual Category Main Board BSE NSE

Min Investment

₹14825

Price Band

₹563-₹593

Issue Size

₹895.00 Cr

Lot Size

25 (per lot)

IPO Dates
img

21 Nov 2025

Open Date

img

25 Nov 2025

Close Date

img

26 Nov 2025

Allotment Date

img

28 Nov 2025

Listing Date

Know Before Investing

Strengths icon

  • Strong R&D drives innovation and product advancement.
  • Experienced leadership with deep industry and functional expertise.
  • Advanced, compliant facilities with global certifications and scalable capacity.
  • Long-standing relationships with global blue-chip and Fortune 500 customers.
  • Market leader with a diversified portfolio in a high-entry-barrier ingredients industry.

Weaknesses icon

  • Top 10 customers contribute 35%+ of revenue, posing concentration risk.
  • 60%+ revenue from one segment poses concentration risk.
  • Quality lapses or audit failures may lead to order loss and reputational harm.
  • Operational concentration in Gujarat exposes the business to regional disruption risks.
  • Delays or failures in new product launches may impact growth and profitability.
  • Unsuccessful acquisitions may strain resources and dilute expected synergies.
  • Regulatory and government approval delays may disrupt operations.

About Sudeep Pharma Limited

Sudeep Pharma is a technology-driven manufacturer of excipients and speciality ingredients for pharmaceutical, food, and nutrition industries. Since 1989, the company has expanded from basic excipients to over 100 products using in-house technologies for encapsulation, spray drying, granulation, and liposomal preparations. The company provides mineral-based ingredients (calcium, zinc, iron, potassium, magnesium) for pharmaceutical and food applications, while developing customized specialty ingredients including micronutrient premixes and encapsulated formulations through its subsidiary SNPL. Operating three manufacturing facilities in Vadodara, Gujarat with 65,579 metric tons capacity, Sudeep Pharma holds USFDA, WHO-GMP, and ISO approvals, serving over 1,100 customers globally including Pfizer, Merck Group, and Danone across 100 countries. Discuss on Trading Q&A

IPO Objectives

1. (i)Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I; and(ii)General corporate purposes.

Company Promoters

Avani Sujit Bhayani

Bhayani Family Trust

Riva Resources Pvt Ltd.

Shanil Sujit Bhayani

Sujeet Jaysukh Bhayani HUF

Sujit Jaysukh Bhayani

How to Apply for IPO

img img

Login

Login to your Bigul Account

Select Lots & Price

Choose the number of lots and price

UPI ID

Enter your UPI ID

UPI Mandate Request

A UPI Mandate Request Triggered

Approve Mandate

Approve the UPI Mandate Request

IPO Allotment

YES Share will be credited. and the amount will be debited

Close

Let's Open Free Demat Account